{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Directory changed to C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "\n",
    "# Define the target directory\n",
    "target_directory = r\"C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\"  # change your directory here\n",
    "\n",
    "# Check if the directory exists\n",
    "if os.path.exists(target_directory):\n",
    "    # Change the current working directory\n",
    "    os.chdir(target_directory)\n",
    "    print(f\"Directory changed to {os.getcwd()}\")\n",
    "else:\n",
    "    print(f\"Directory {target_directory} does not exist.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from src.pipeline.paprocessing.run import PAProcessingPipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2024-11-18 19:23:25,769 - micro - MainProcess - INFO     Container 'pre-auth-policies' already exists. (blob_helper.py:_create_container_if_not_exists:86)\n",
      "C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\src\\cosmosdb\\cosmosmongodb_helper.py:31: UserWarning: You appear to be connected to a CosmosDB cluster. For more information regarding feature compatibility and support please visit https://www.mongodb.com/supportability/cosmosdb\n",
      "  self.client = pymongo.MongoClient(connection_string)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Templates found: ['ner_clinician_system.jinja', 'ner_clinician_user.jinja', 'ner_patient_system.jinja', 'ner_patient_user.jinja', 'ner_physician_system.jinja', 'ner_physician_user.jinja', 'ner_system_prompt.jinja', 'ner_user_prompt.jinja', 'prior_auth_o1_user_prompt.jinja', 'prior_auth_o1_user_prompt_b.jinja', 'prior_auth_system_prompt.jinja', 'prior_auth_user_prompt.jinja', 'query_expansion_system_prompt.jinja', 'query_expansion_user_prompt.jinja', 'summarize_policy_system.jinja', 'summarize_policy_user.jinja']\n"
     ]
    }
   ],
   "source": [
    "from src.pipeline.paprocessing.prompt_manager import PromptManager\n",
    "from src.pipeline.paprocessing.run import PAProcessingPipeline\n",
    "\n",
    "pa_pipeline = PAProcessingPipeline(send_cloud_logs=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2024-11-18 19:23:38,306 - micro - MainProcess - INFO     Found 3 files with extensions ['pdf'] (helpers.py:find_all_files:31)\n"
     ]
    }
   ],
   "source": [
    "uploaded_files = (\n",
    "    r\"C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\"\n",
    ")\n",
    "from src.pipeline.paprocessing.helpers import find_all_files\n",
    "\n",
    "files = find_all_files(uploaded_files, [\"pdf\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2024-11-18 18:23:52,386 - PAProcessing - MainProcess - INFO     PAProcessing started db96f016. (run.py:run:767)\n",
      "2024-11-18 18:23:52,706 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf' uploaded to blob 'pa_proccesing_runs/db96f016/raw_uploaded_files/003_a (note) .pdf' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:52,709 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/raw_uploaded_files/003_a (note) .pdf' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:52,827 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf' uploaded to blob 'pa_proccesing_runs/db96f016/raw_uploaded_files/003_a (labs).pdf' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:52,828 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/raw_uploaded_files/003_a (labs).pdf' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:53,112 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf' uploaded to blob 'pa_proccesing_runs/db96f016/raw_uploaded_files/003_a (form).pdf' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:53,113 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/raw_uploaded_files/003_a (form).pdf' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:53,116 - PAProcessing - MainProcess - INFO     All files processed for upload to Azure Blob Storage in container 'pre-auth-policies'. (run.py:upload_files_to_blob:238)\n",
      "2024-11-18 18:23:53,456 - micro - MainProcess - INFO     Container 'pre-auth-policies' already exists. (blob_helper.py:_create_container_if_not_exists:86)\n",
      "2024-11-18 18:23:53,456 - micro - MainProcess - INFO     AzureBlobManager initialized successfully. (pdfhandler.py:__init__:42)\n",
      "2024-11-18 18:23:53,456 - PAProcessing - MainProcess - INFO     Processing file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf (run.py:process_uploaded_files:254)\n",
      "2024-11-18 18:23:53,456 - micro - MainProcess - INFO     Input path is a local file or directory: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf (pdfhandler.py:extract_images_from_pdf:101)\n",
      "2024-11-18 18:23:53,456 - micro - MainProcess - INFO     Opening file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf (pdfhandler.py:_process_single_pdf:230)\n",
      "2024-11-18 18:23:53,489 - micro - MainProcess - INFO     Processing page 1 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:53,591 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-1.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:53,591 - micro - MainProcess - INFO     Processing page 2 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:53,711 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-2.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:53,713 - micro - MainProcess - INFO     Processing page 3 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\doctor_notes\\003_a (note) .pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:53,796 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-3.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:53,920 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-1.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (note) -page-1.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:53,922 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-1.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (note) -page-1.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:54,039 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-2.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (note) -page-2.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:54,039 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-2.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (note) -page-2.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:54,158 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-3.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (note) -page-3.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:54,158 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-3.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (note) -page-3.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:54,158 - PAProcessing - MainProcess - INFO     All files processed for upload to Azure Blob Storage in container 'pre-auth-policies'. (run.py:upload_files_to_blob:238)\n",
      "2024-11-18 18:23:54,158 - PAProcessing - MainProcess - INFO     Images extracted and uploaded from: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t (run.py:process_uploaded_files:264)\n",
      "2024-11-18 18:23:54,158 - PAProcessing - MainProcess - INFO     Processing file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf (run.py:process_uploaded_files:254)\n",
      "2024-11-18 18:23:54,158 - micro - MainProcess - INFO     Input path is a local file or directory: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf (pdfhandler.py:extract_images_from_pdf:101)\n",
      "2024-11-18 18:23:54,158 - micro - MainProcess - INFO     Opening file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf (pdfhandler.py:_process_single_pdf:230)\n",
      "2024-11-18 18:23:54,179 - micro - MainProcess - INFO     Processing page 1 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:54,266 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-1.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:54,268 - micro - MainProcess - INFO     Processing page 2 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\labs\\003_a (labs).pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:54,363 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-2.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:54,488 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-1.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (labs)-page-1.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:54,489 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-1.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (labs)-page-1.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:54,618 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-2.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (labs)-page-2.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:54,620 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-2.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (labs)-page-2.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:54,622 - PAProcessing - MainProcess - INFO     All files processed for upload to Azure Blob Storage in container 'pre-auth-policies'. (run.py:upload_files_to_blob:238)\n",
      "2024-11-18 18:23:54,626 - PAProcessing - MainProcess - INFO     Images extracted and uploaded from: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t (run.py:process_uploaded_files:264)\n",
      "2024-11-18 18:23:54,628 - PAProcessing - MainProcess - INFO     Processing file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf (run.py:process_uploaded_files:254)\n",
      "2024-11-18 18:23:54,630 - micro - MainProcess - INFO     Input path is a local file or directory: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf (pdfhandler.py:extract_images_from_pdf:101)\n",
      "2024-11-18 18:23:54,632 - micro - MainProcess - INFO     Opening file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf (pdfhandler.py:_process_single_pdf:230)\n",
      "2024-11-18 18:23:54,666 - micro - MainProcess - INFO     Processing page 1 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:54,842 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-1.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:54,842 - micro - MainProcess - INFO     Processing page 2 of 'C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\utils\\data\\cases\\003\\a\\pa_form\\003_a (form).pdf' (pdfhandler.py:_process_single_pdf:235)\n",
      "2024-11-18 18:23:54,939 - micro - MainProcess - INFO     Saved image: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-2.png (pdfhandler.py:_process_single_pdf:243)\n",
      "2024-11-18 18:23:55,106 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-1.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (form)-page-1.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:55,110 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-1.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (form)-page-1.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:55,236 - micro - MainProcess - INFO     File 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-2.png' uploaded to blob 'pa_proccesing_runs/db96f016/processed_images/003_a (form)-page-2.png' successfully. (blob_helper.py:_upload_single_file:198)\n",
      "2024-11-18 18:23:55,238 - PAProcessing - MainProcess - INFO     Uploaded file 'C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-2.png' to blob 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/db96f016/processed_images/003_a (form)-page-2.png' in container 'pre-auth-policies'. (run.py:upload_files_to_blob:228)\n",
      "2024-11-18 18:23:55,238 - PAProcessing - MainProcess - INFO     All files processed for upload to Azure Blob Storage in container 'pre-auth-policies'. (run.py:upload_files_to_blob:238)\n",
      "2024-11-18 18:23:55,238 - PAProcessing - MainProcess - INFO     Images extracted and uploaded from: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t (run.py:process_uploaded_files:264)\n",
      "2024-11-18 18:23:55,238 - PAProcessing - MainProcess - INFO     Files processed and images extracted to: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t (run.py:process_uploaded_files:266)\n",
      "2024-11-18 18:23:55,238 - micro - MainProcess - INFO     Found 7 files with extensions ['png'] (helpers.py:find_all_files:31)\n",
      "2024-11-18 18:23:55,238 - PAProcessing - MainProcess - INFO     \n",
      "Extracting patient data... (run.py:extract_patient_data:431)\n",
      "2024-11-18 18:23:55,238 - micro - MainProcess - INFO     Function generate_chat_response started at 2024-11-18 18:23:55 (aoai_helper.py:generate_chat_response:370)\n",
      "2024-11-18 18:23:55,350 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,358 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,360 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,366 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,370 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,376 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,380 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-3.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:23:55,380 - micro - MainProcess - INFO     Sending request to Azure OpenAI at 2024-11-18 18:23:55 (aoai_helper.py:generate_chat_response:427)\n",
      "2024-11-18 18:24:02,441 - micro - MainProcess - INFO     Function generate_chat_response finished at 2024-11-18 18:24:02 (Duration: 7.20 seconds) (aoai_helper.py:generate_chat_response:481)\n",
      "2024-11-18 18:24:02,441 - PAProcessing - MainProcess - DEBUG    Data logged for case 'db96f016' at step 'patient_information_extraction'. (run.py:log_output:333)\n",
      "2024-11-18 18:24:02,441 - PAProcessing - MainProcess - INFO     \n",
      "Extracting physician data... (run.py:extract_physician_data:464)\n",
      "2024-11-18 18:24:02,441 - micro - MainProcess - INFO     Function generate_chat_response started at 2024-11-18 18:24:02 (aoai_helper.py:generate_chat_response:370)\n",
      "2024-11-18 18:24:02,441 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,455 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,458 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,463 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,467 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,470 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,475 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-3.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:02,477 - micro - MainProcess - INFO     Sending request to Azure OpenAI at 2024-11-18 18:24:02 (aoai_helper.py:generate_chat_response:427)\n",
      "2024-11-18 18:24:07,159 - micro - MainProcess - INFO     Function generate_chat_response finished at 2024-11-18 18:24:07 (Duration: 4.72 seconds) (aoai_helper.py:generate_chat_response:481)\n",
      "2024-11-18 18:24:07,162 - PAProcessing - MainProcess - DEBUG    Data logged for case 'db96f016' at step 'physician_information_extraction'. (run.py:log_output:333)\n",
      "2024-11-18 18:24:07,166 - PAProcessing - MainProcess - INFO     \n",
      "Extracting clinician data... (run.py:extract_clinician_data:497)\n",
      "2024-11-18 18:24:07,170 - micro - MainProcess - INFO     Function generate_chat_response started at 2024-11-18 18:24:07 (aoai_helper.py:generate_chat_response:370)\n",
      "2024-11-18 18:24:07,174 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,179 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (form)-page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,183 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,188 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (labs)-page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,193 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-1.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,198 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-2.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,202 - micro - MainProcess - INFO     Image C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t\\003_a (note) -page-3.png type: image/png (aoai_helper.py:generate_chat_response:413)\n",
      "2024-11-18 18:24:07,204 - micro - MainProcess - INFO     Sending request to Azure OpenAI at 2024-11-18 18:24:07 (aoai_helper.py:generate_chat_response:427)\n",
      "2024-11-18 18:24:22,656 - micro - MainProcess - INFO     Function generate_chat_response finished at 2024-11-18 18:24:22 (Duration: 15.49 seconds) (aoai_helper.py:generate_chat_response:481)\n",
      "2024-11-18 18:24:22,660 - PAProcessing - MainProcess - DEBUG    Data logged for case 'db96f016' at step 'clinical_information_extraction'. (run.py:log_output:333)\n",
      "2024-11-18 18:24:22,695 - PAProcessing - MainProcess - INFO     Expanding query and searching for policy... (run.py:expand_query_and_search_policy:590)\n",
      "2024-11-18 18:24:22,697 - PAProcessing - MainProcess - INFO     Input clinical information: diagnosis='B-cell precursor acute lymphoblastic leukemia (B-ALL); Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal Residual Disease (MRD+)' icd_10_code='C91.00' prior_treatments_and_results='Vincristine: Administered weekly during induction phase; Dexamethasone: Administered daily for 28 days during induction phase; L-asparaginase: Administered on alternate days during induction phase; Daunorubicin: Given as a single dose during the first week of induction phase; Methotrexate: High-dose, given weekly during consolidation phase; Mercaptopurine: Daily oral administration during consolidation phase; Vincristine: Administered biweekly during consolidation phase; Cyclophosphamide: Given during the third week of consolidation phase; Doxorubicin: Administered during the final week of consolidation phase; Methotrexate: Weekly doses during maintenance phase; Mercaptopurine: Daily oral administration during maintenance phase; Vincristine: Every 4 weeks during maintenance phase; Intrathecal Methotrexate: Plan to administer every 2-3 months for CNS prophylaxis' specific_drugs_taken_and_failures='Vincristine: Administered weekly during induction phase; Dexamethasone: Administered daily for 28 days during induction phase; L-asparaginase: Administered on alternate days during induction phase; Daunorubicin: Given as a single dose during the first week of induction phase; Methotrexate: High-dose, given weekly during consolidation phase; Mercaptopurine: Daily oral administration during consolidation phase; Vincristine: Administered biweekly during consolidation phase; Cyclophosphamide: Given during the third week of consolidation phase; Doxorubicin: Administered during the final week of consolidation phase; Methotrexate: Weekly doses during maintenance phase; Mercaptopurine: Daily oral administration during maintenance phase; Vincristine: Every 4 weeks during maintenance phase; Intrathecal Methotrexate: Plan to administer every 2-3 months for CNS prophylaxis' alternative_drugs_required='Not provided' relevant_lab_results_or_imaging='White Blood Cell Count (WBC): 4,500 - 10,000 cells/µL; Neutrophils: 40% - 60%; Lymphocytes: 20% - 40%; Monocytes: 2% - 8%; Eosinophils: 1% - 4%; Basophils: 0% - 1%; Hemoglobin (Hgb): 11.5 - 15.5 g/dL; Hematocrit (Hct): 35% - 45%; Platelet Count: 150,000 - 450,000 cells/µL; Bone Marrow Cellularity: Hypercellular (approximately 90% cellularity); Blast Cell Percentage: Less than 5% blast cells, consistent with clinical remission; Minimal Residual Disease (MRD) Status: Positive for minimal residual disease (MRD+); Leukemic Cell Percentage: 0.1% leukemic cells detected' symptom_severity_and_impact='Positive for fatigue; Mild fatigue and decreased energy' prognosis_and_risk_if_not_approved='The presence of minimal residual disease suggests residual leukemic activity. Continuous monitoring and further therapeutic intervention may be warranted.' clinical_rationale_for_urgency='Not provided' treatment_request=TreatmentRequest(name_of_medication_or_procedure='Blinatumomab', code_of_medication_or_procedure='Not provided', dosage='28 mcg/day', duration='Induction cycle 1: Days 1-28: 28 mcg/day; Based on clinical response, up to 6 months', rationale='Initiate Blinatumomab therapy for management of MRD+ B-ALL.', presumed_eligibility='Yes') (run.py:expand_query_and_search_policy:591)\n",
      "2024-11-18 18:24:22,697 - micro - MainProcess - INFO     Function generate_chat_response started at 2024-11-18 18:24:22 (aoai_helper.py:generate_chat_response:370)\n",
      "2024-11-18 18:24:22,701 - micro - MainProcess - INFO     Sending request to Azure OpenAI at 2024-11-18 18:24:22 (aoai_helper.py:generate_chat_response:427)\n",
      "2024-11-18 18:24:24,469 - micro - MainProcess - INFO     Function generate_chat_response finished at 2024-11-18 18:24:24 (Duration: 1.77 seconds) (aoai_helper.py:generate_chat_response:481)\n",
      "2024-11-18 18:24:24,471 - PAProcessing - MainProcess - DEBUG    Data logged for case 'db96f016' at step 'query_expansion'. (run.py:log_output:333)\n",
      "2024-11-18 18:24:24,474 - PAProcessing - MainProcess - INFO     API response query: {'response': {'optimized_query': 'Prior authorization for Blinatumomab for B-cell precursor acute lymphoblastic leukemia (B-ALL), Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL), Minimal Residual Disease (MRD+). Related terms: B-ALL, B-cell ALL, acute lymphoblastic leukemia, Philadelphia chromosome-negative ALL, MRD positive, minimal residual disease, Blincyto, CD19-targeted therapy, immunotherapy for leukemia, 28 mcg/day dosage, induction cycle, up to 6 months treatment, leukemia treatment, hematologic malignancies, targeted therapy for leukemia.'}, 'conversation_history': [{'role': 'system', 'content': '## Role:\\nYou are an expert in search engine optimization for healthcare and prior authorization processes, specializing in **query expansion** techniques to improve search recall. Your goal is to generate expanded search queries based on **Diagnosis and Medical Justification** and **Medication or Procedure** provided by the user.\\n\\n## Task:\\nYour task is to review the clinical evaluation and documentation provided in JSON format and return a query that will maximize the likelihood of finding the exact matching policy.\\n\\n## Instructions\\n1. Focus exclusively on the **Diagnosis and Medical Justification** and the **Medication or Procedure**.\\n2. Apply **query expansion** to generate alternative terms, synonyms, and related medical concepts for both diagnosis and treatment.\\n3. Prioritize high recall in retrieval by generating similar queries that cover different medical terminologies and synonyms for the given input.\\n4. Ensure expanded queries include related conditions, procedural codes, and alternative names to broaden the scope of search results.\\n5. Use semantic search techniques to improve retrieval based on context and meaning, not just keywords.\\n\\nKey Elements to Expand:\\n- **Diagnosis and Medical Justification**\\n- **Medication or Procedure**\\n\\nOutput Format:\\n- Return a JSON object with the expanded queries under the key `\"optimized_query\"`.'}, {'role': 'user', 'content': [{'type': 'text', 'text': '##Role:\\nYou are an expert in optimizing prior authorization searches using query expansion techniques for clinical data.\\n\\n##Task:\\nYour goal is to construct an optimized search query based on the provided Diagnosis and Medical Justification and Plan for Treatment or Request for Prior Authorization. Use query expansion to generate similar terms, synonyms, and related medical concepts, improving retrieval recall and ensuring accurate policy matching in Azure AI Search.\\n\\n##Instructions:\\n\\n  1. **Focus on the Following Key Elements:**\\n\\n  - **Diagnosis and Medical Justification:** B-cell precursor acute lymphoblastic leukemia (B-ALL); Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal Residual Disease (MRD+)\\n  - **Plan for Treatment or Request for Prior Authorization:**\\n    - **Medication or Procedure:** Blinatumomab\\n    - **Code:** Not provided\\n    - **Dosage or Plan:** 28 mcg/day\\n    - **Duration:** Induction cycle 1: Days 1-28: 28 mcg/day; Based on clinical response, up to 6 months\\n    - **Rationale:** Initiate Blinatumomab therapy for management of MRD+ B-ALL.\\n\\n  2. **Apply Query Expansion Techniques:**\\n    - Generate alternative terms, synonyms, and related medical concepts for both the diagnosis and the medication/procedure.\\n    - Include relevant medical codes (e.g., ICD-10, CPT) and any known synonyms or alternative names.\\n    - Maximize recall by covering different ways the diagnosis or treatment might be described in medical policies.\\n\\n  3. Construct the Optimized Search Query:**\\n    - Combine the key elements and expanded terms into a cohesive search query.\\n    - Ensure the query remains focused and relevant to the specific case.\\n    - Prioritize high recall while maintaining acceptable precision.\\n\\n  4. **Handle Insufficient Information:**\\n\\n    - If relevant codes are not provided (e.g., ICD-10, CPT) but the Diagnosis and Medical Justification or Medication or Procedure is available, proceed with the available information.\\n    - If either the Diagnosis and Medical Justification or the Medication or Procedure is completely missing, return the following message:\\n\\n    ```json\\n    {\\n      \"optimized_query\": \"Need more information to construct the query.\"\\n    }\\n    ```\\n\\n  5. Provide the final query in a JSON object as shown:\\n    ```\\n    {\\n      \"optimized_query\": \"\" // Add the constructed query here\\n    }\\n    ```\\n\\n##Example Query Construction:\\n\\n**Key Elements:**\\n\\n- **Diagnosis and Medical Justification:** Lennox-Gastaut Syndrome (ICD-10: Not provided)\\n- **Medication or Procedure:** Epidiolex\\n  - **Code:** Not provided\\n  - **Dosage:** 100 mg/mL\\n  - **Duration:** Take 2.5mg/kg/day divided in two doses for one week, then increase to 5mg/kg/day divided in two doses\\n  - **Rationale:** Patient\\'s seizures are worse in frequency and more varied in semiology despite trial of several AEDs\\n\\n**Constructed Search Query with Query Expansion:**\\n```json\\n{\\n  \"optimized_query\": \"Prior authorization for Epidiolex for Lennox-Gastaut Syndrome. Related terms: LGS, severe epilepsy, cannabidiol, CBD oil, seizure medication, anti-epileptic drugs, AEDs.\"\\n}\\n```\\n\\n##Output: Please generate a JSON output based on:\\n\\n**Key Elements:**\\n- **Diagnosis and Medical Justification:** B-cell precursor acute lymphoblastic leukemia (B-ALL); Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal Residual Disease (MRD+)\\n- **Plan for Treatment or Request for Prior Authorization:**\\n  - **Medication or Procedure:** Blinatumomab\\n  - **Code:** Not provided\\n  - **Dosage or Plan:** 28 mcg/day\\n  - **Duration:** Induction cycle 1: Days 1-28: 28 mcg/day; Based on clinical response, up to 6 months\\n  - **Rationale:** Initiate Blinatumomab therapy for management of MRD+ B-ALL.\\n\\n\\n**Constructed Search Query with Query Expansion:**\\n```json\\n{\\n  \"optimized_query\": \"\" //add here the construcutue query \\n}\\n```'}]}, {'role': 'assistant', 'content': '{\\n  \"optimized_query\": \"Prior authorization for Blinatumomab for B-cell precursor acute lymphoblastic leukemia (B-ALL), Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL), Minimal Residual Disease (MRD+). Related terms: B-ALL, B-cell ALL, acute lymphoblastic leukemia, Philadelphia chromosome-negative ALL, MRD positive, minimal residual disease, Blincyto, CD19-targeted therapy, immunotherapy for leukemia, 28 mcg/day dosage, induction cycle, up to 6 months treatment, leukemia treatment, hematologic malignancies, targeted therapy for leukemia.\"\\n}'}]} (run.py:expand_query_and_search_policy:610)\n",
      "2024-11-18 18:24:25,811 - micro - MainProcess - INFO     Downloaded blob 'policies_ocr/003.pdf' as bytes. (blob_helper.py:download_blob_to_bytes:308)\n",
      "2024-11-18 18:24:25,812 - PAProcessing - MainProcess - INFO     Blob content downloaded successfully from https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/003.pdf (run.py:get_policy_text_from_blob:283)\n",
      "2024-11-18 18:24:34,417 - PAProcessing - MainProcess - INFO     Document analyzed successfully for blob https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/003.pdf (run.py:get_policy_text_from_blob:291)\n",
      "2024-11-18 18:24:34,420 - PAProcessing - MainProcess - DEBUG    Data logged for case 'db96f016' at step 'policy_extraction'. (run.py:log_output:333)\n",
      "2024-11-18 18:24:34,446 - PAProcessing - MainProcess - INFO     Generating final determination for db96f016 (run.py:generate_final_determination:660)\n",
      "2024-11-18 18:24:34,450 - PAProcessing - MainProcess - INFO     Input clinical information: **Task:**\n",
      "\n",
      "Analyze a prior authorization request for a medical treatment or medication using the provided patient information, physician information, clinical information, and policy text.\n",
      "\n",
      "---\n",
      "\n",
      "**Purpose:**\n",
      "\n",
      "Determine whether the prior authorization request should be Approved, Denied, or if More Information is Needed.\n",
      "\n",
      "---\n",
      "\n",
      "**Approach:**\n",
      "\n",
      "- Analyze all policy criteria by thoroughly reviewing the policy text.\n",
      "- Extract necessary information from the policy and the provided data.\n",
      "- Compare the extracted information from the patient, physician, and clinical data against the policy criteria.\n",
      "- Make a detailed decision based on these comparisons.\n",
      "\n",
      "---\n",
      "\n",
      "**Instructions:**\n",
      "\n",
      "**Analyze Policy Criteria:**\n",
      "\n",
      "- Carefully read the entire policy text relevant to the requested medication or procedure.\n",
      "- Extract and list every key criterion and requirement, including but not limited to:\n",
      "  - Specific conditions and diagnoses.\n",
      "  - Prior treatment requirements.\n",
      "  - Dosage limitations and guidelines.\n",
      "  - Patient eligibility criteria.\n",
      "  - Physician qualifications.\n",
      "  - Required diagnostic tests or lab results.\n",
      "  - Exclusions and contraindications.\n",
      "  - Authorization duration and renewal criteria.\n",
      "- Pay special attention to qualifying statements such as \"and,\" \"or,\" \"must,\" \"should,\" \"unless,\" \"except,\" and \"if.\"\n",
      "\n",
      "**Extract Necessary Information from Provided Data:**\n",
      "\n",
      "- From the patient, physician, and clinical information, extract relevant details that correspond to each policy criterion.\n",
      "- Ensure no important information is overlooked.\n",
      "\n",
      "**Compare Information:**\n",
      "\n",
      "- For each policy criterion, compare it with the extracted data from the patient and clinical information.\n",
      "- Indicate whether each criterion is Fully Met, Partially Met, or Not Met.\n",
      "- Provide evidence from the data and cite relevant sections of the policy text.\n",
      "\n",
      "**Identify Gaps or Missing Information:**\n",
      "\n",
      "- Note any missing details that prevent a full evaluation.\n",
      "- Specify additional information required, if any, and explain why it is necessary.\n",
      "\n",
      "**Make a Detailed Decision:**\n",
      "\n",
      "- Based on the comprehensive comparison, decide if the request should be Approved, Denied, or if More Information is Needed.\n",
      "- Justify the decision with logical reasoning and evidence from the provided information and policy text.\n",
      "\n",
      "---\n",
      "\n",
      "**Decision Criteria:**\n",
      "\n",
      "- **Approved:** The request meets all the criteria outlined in the policy text.\n",
      "- **Denied:** The request does not meet one or more of the criteria outlined in the policy text. If any criterion is not met or only partially met, the request must be denied.\n",
      "- **Needs More Information:** Additional information is required to make a decision. Specify what is needed and why. If a specific criterion from the policy text is not demonstrated in the clinical information (such as prior or alternative treatments), assume it is absent and deny the request. If other physician or patient information is unclear or ambiguous, additional information can be requested.\n",
      "\n",
      "---\n",
      "\n",
      "**Patient Information:**\n",
      "\n",
      "- Patient Name: Lucas Little\n",
      "- Date of Birth: 07/30/2017\n",
      "- Patient ID: 345987\n",
      "- Address: 28 Dearborn St, Chicago, IL, 60602\n",
      "- Phone Number: 555-360-8746\n",
      "\n",
      "---\n",
      "\n",
      "**Physician Information:**\n",
      "\n",
      "- Physician Name: Dr. Oncoso\n",
      "- Specialty: Pediatric Hematology and Oncology\n",
      "- **Contact Information:**\n",
      "  - Office Phone: 555-324-7878\n",
      "  - Fax: 555-324-7877\n",
      "  - Address: 27 W State St, Chicago, IL 60601\n",
      "\n",
      "---\n",
      "\n",
      "**Clinical Information:**\n",
      "\n",
      "- Diagnosis: B-cell precursor acute lymphoblastic leukemia (B-ALL); Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal Residual Disease (MRD+)\n",
      "- ICD-10 Code: C91.00\n",
      "- History of Prior Treatments and Results: Vincristine: Administered weekly during induction phase; Dexamethasone: Administered daily for 28 days during induction phase; L-asparaginase: Administered on alternate days during induction phase; Daunorubicin: Given as a single dose during the first week of induction phase; Methotrexate: High-dose, given weekly during consolidation phase; Mercaptopurine: Daily oral administration during consolidation phase; Vincristine: Administered biweekly during consolidation phase; Cyclophosphamide: Given during the third week of consolidation phase; Doxorubicin: Administered during the final week of consolidation phase; Methotrexate: Weekly doses during maintenance phase; Mercaptopurine: Daily oral administration during maintenance phase; Vincristine: Every 4 weeks during maintenance phase; Intrathecal Methotrexate: Plan to administer every 2-3 months for CNS prophylaxis\n",
      "- Specific Drugs Taken and Outcomes: Vincristine: Administered weekly during induction phase; Dexamethasone: Administered daily for 28 days during induction phase; L-asparaginase: Administered on alternate days during induction phase; Daunorubicin: Given as a single dose during the first week of induction phase; Methotrexate: High-dose, given weekly during consolidation phase; Mercaptopurine: Daily oral administration during consolidation phase; Vincristine: Administered biweekly during consolidation phase; Cyclophosphamide: Given during the third week of consolidation phase; Doxorubicin: Administered during the final week of consolidation phase; Methotrexate: Weekly doses during maintenance phase; Mercaptopurine: Daily oral administration during maintenance phase; Vincristine: Every 4 weeks during maintenance phase; Intrathecal Methotrexate: Plan to administer every 2-3 months for CNS prophylaxis\n",
      "- Alternative Drugs Required: Not provided\n",
      "- Lab Results or Diagnostic Imaging: White Blood Cell Count (WBC): 4,500 - 10,000 cells/µL; Neutrophils: 40% - 60%; Lymphocytes: 20% - 40%; Monocytes: 2% - 8%; Eosinophils: 1% - 4%; Basophils: 0% - 1%; Hemoglobin (Hgb): 11.5 - 15.5 g/dL; Hematocrit (Hct): 35% - 45%; Platelet Count: 150,000 - 450,000 cells/µL; Bone Marrow Cellularity: Hypercellular (approximately 90% cellularity); Blast Cell Percentage: Less than 5% blast cells, consistent with clinical remission; Minimal Residual Disease (MRD) Status: Positive for minimal residual disease (MRD+); Leukemic Cell Percentage: 0.1% leukemic cells detected\n",
      "- Symptom Severity and Impact on Daily Life: Positive for fatigue; Mild fatigue and decreased energy\n",
      "- Prognosis and Risk if Not Approved: The presence of minimal residual disease suggests residual leukemic activity. Continuous monitoring and further therapeutic intervention may be warranted.\n",
      "- Clinical Rationale for Urgency: Not provided\n",
      "\n",
      "---\n",
      "\n",
      "**Treatment Plan:**\n",
      "\n",
      "- Requested Medication or Procedure: Blinatumomab\n",
      "- Medication or Procedure Code: Not provided\n",
      "- Dosage: 28 mcg/day\n",
      "- Duration: \n",
      "- Rationale: Initiate Blinatumomab therapy for management of MRD+ B-ALL.\n",
      "- Presumed Eligibility: Yes\n",
      "\n",
      "---\n",
      "\n",
      "**Policy Text:**\n",
      "\n",
      "<figure>\n",
      "\n",
      "![](figures/0)\n",
      "\n",
      "<!-- FigureContent=\"envolve. Pharmacy Solutions\" -->\n",
      "\n",
      "</figure>\n",
      "\n",
      "\n",
      "Clinical Policy: Blinatumomab (Blincyto) Reference Number: ERX.SPA.241 Effective Date: 09.01.18 Last Review Date: 08.18\n",
      "\n",
      "Revision Log\n",
      "\n",
      "See Important Reminder at the end of this policy for important regulatory and legal information.\n",
      "\n",
      "Description Blinatumomab (Blincyto®) is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells).\n",
      "\n",
      "\n",
      "# FDA Approved Indication(s) Blincyto is indicated for:\n",
      "\n",
      "• MRD-positive B-cell precursor ALL\n",
      "\n",
      "o Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\n",
      "\n",
      "· Relapsed or refractory B-cell precursor ALL\n",
      "\n",
      "o Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.\n",
      " :unselected:\n",
      "Policy/Criteria\n",
      "\n",
      "Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.\n",
      "\n",
      "It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Blincyto is medically necessary when the following criteria are met:\n",
      "\n",
      "I. Initial Approval Criteria\n",
      "\n",
      "A. Acute Lymphoblastic Leukemia (must meet all):\n",
      "\n",
      "1\\. Diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL);\n",
      "\n",
      "2\\. Prescribed by or in consultation with an oncologist or hematologist;\n",
      "\n",
      "3\\. Requested as treatment for (a or b):\n",
      "\n",
      "a. B-ALL in remission but positive for minimal residual disease (MRD+);\n",
      "\n",
      "b. Relapsed or refractory B-ALL (i and ii):\n",
      "\n",
      "i. Philadelphia chromosome-negative (Ph-) disease;\n",
      "\n",
      "ii. Philadelphia chromosome-positive (Ph+) disease and intolerant or refractory to at least one second-generation or later tyrosine kinase inhibitor (TKI; i.e., Sprycel®, Tasigna®, Bosulif®, Iclusig®);\n",
      "\n",
      "\\*Prior authorization is (or may be) required for these agents\n",
      "\n",
      "4\\. Dose does not exceed 28 mcg/day. Approval duration: 6 months\n",
      "\n",
      "B. Other diagnoses/indications\n",
      "\n",
      "1\\. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III\n",
      "\n",
      "(Diagnoses/Indications for which coverage is NOT authorized).\n",
      "\n",
      "\n",
      "# II. Continued Therapy\n",
      "\n",
      "A. Acute Lymphoblastic Leukemia (must meet all):\n",
      "\n",
      "1\\. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Blincyto for a covered indication and has received this medication for at least 30 days;\n",
      "\n",
      "2\\. Member is responding positively to therapy;\n",
      "\n",
      "<!-- PageNumber=\"Page 1 of 4\" -->\n",
      "\n",
      "<!-- PageHeader=\"CLINICAL POLICY Blinatumomab\" -->\n",
      "\n",
      "<figure>\n",
      "\n",
      "![](figures/1)\n",
      "\n",
      "<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\n",
      "\n",
      "</figure>\n",
      "\n",
      "\n",
      "3\\. If request is for a dose increase, new dose does not exceed 28 mcg/day. Approval duration: 12 months\n",
      "\n",
      "B. Other diagnoses/indications (must meet 1 or 2):\n",
      "\n",
      "1\\. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.\n",
      "\n",
      "Approval duration: Duration of request or 6 months (whichever is less); or\n",
      "\n",
      "2\\. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).\n",
      "\n",
      "III. Diagnoses/Indications for which coverage is NOT authorized:\n",
      "\n",
      "A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy - ERX.PA.01 or evidence of coverage documents.\n",
      "\n",
      "\n",
      "# IV. Appendices/General Information\n",
      "\n",
      "Appendix A: Abbreviation/Acronym Key B-ALL: B-cell precursor acute lymphoblastic leukemia CR: complete remission\n",
      "\n",
      "FDA: Food and Drug Administration MRD+: positive minimal residual disease TKI: tyrosine kinase inhibitor\n",
      "\n",
      "Appendix B: Therapeutic Alternatives This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.\n",
      "\n",
      "| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |\n",
      "| - | - | - |\n",
      "| Sprycel® (dasatinib) | 140 mg PO QD (adults\\*) | 180 mg/day |\n",
      "| Iclusig® (ponatinib) | 45 mg PO QD (adults\\*) | 45 mg/day |\n",
      "| Tasigna® (nilotinib) | 400 mg PO BID (off-label use; adults\\* - as referenced in Kim, et al., 2015; see also Appendix D) | 800 mg/day |\n",
      "| Bosulif® (bosutinib) | 500 to 600 mg PO QD (off-label use; adults\\* - as referenced in Gambacroti-Passerini, et al., 2015; see also Appendix D). | 600 mg/day |\n",
      "\n",
      "Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.\n",
      "\n",
      "\\*Sprycel and Iclusig are FDA approved for Ph+ ALL in adults; however, all four listed TKIs are NCCN recommended (category 2A) for Ph+ ALL in both adults and adolescents/young adults.\n",
      "\n",
      "Appendix C: Contraindications Not applicable\n",
      "\n",
      "Appendix D: General Information\n",
      "\n",
      ". MRD-positive B-cell precursor ALL\n",
      "\n",
      "In 2018, Blincyto received FDA approval for MRD+ B-ALL in remission based on a single- o arm, open label study (BLAST) showing complete MRD response in a majority of adults undergoing Blincyto therapy; the new FDA indication includes both children and adults based on this pivotal trial.\n",
      "\n",
      "o In 2017, blinatumomab's labeled use was expanded from treatment of Ph- relapsed/refractory • Relapsed or refractory B-cell precursor ALL\n",
      "\n",
      "B-ALL to treatment of Ph+ disease based on a single-arm, open label study (ALCANTARAA) showing complete remission (CR), or CR with partial hematologic recovery, after disease progression on at least one second- or thid-generation TKI. FDA approved second- and third- generation TKIs for Ph+ ALL in adults include Sprycel and Iclusig. NCCN recommended (category 2A) TKIs for Ph+ ALL in adults and adolescents/young adults include Sprycel, Iclusig, Tasigna and Bosulif.\n",
      "\n",
      "<!-- PageNumber=\"Page 2 of 4\" -->\n",
      "\n",
      "CLINICAL POLICY Blinatumomab\n",
      "\n",
      "<figure>\n",
      "\n",
      "![](figures/2)\n",
      "\n",
      "<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\n",
      "\n",
      "</figure>\n",
      "\n",
      "\n",
      "\n",
      "# V. Dosage and Administration\n",
      "\n",
      "| Indication || Dosing Regimen  | Maximum Dose |\n",
      "| - | - | - | - |\n",
      "| B-ALL (MRD+ in | Treatment course: 1 cycle of Blincyto IV for induction followed by up to 3 additional cycles for consolidation. || 28 mcg/day |\n",
      "| remission) | Patients ≥ 45 kg receive a fixed dose • |\n",
      "|| || o Induction cycle 1 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval\n",
      "|| || :unselected: :unselected: | o Consolidation cycles 2-4 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval |\n",
      "|| || Patients < 45 kg based on body surface area (BSA) • |\n",
      "|| || o :unselected: Induction cycle 1 . Days 1-7: 5 mcg/m2/day |\n",
      "|||\n",
      "|| || || · Days 8-28: 15 mcg/m2/day . Days 29-42: 14-day treatment-free interval |\n",
      "|||\n",
      "|| || || :unselected: o Consolidation cycles 2-4 Days 1-28: 15 mcg/m2/day |\n",
      "|| || Days 29-42: 14-day treatment-free interval || |\n",
      "| B-ALL (relapsed or | Treatment course: 2 cycles of Blincyto IV for induction followed by 3 cycles for consolidation and up to 4 cycles of continued therapy. || 28 mcg/day |\n",
      "|||| |\n",
      "| refractory) | Patients ≥ 45 kg receive a fixed dose • |\n",
      "|| || o Induction cycle 1 . Days 1-7: 9 mcg/day . Days 8-28: 28 mcg/day Days 29-42: 14-day treatment-free interval . :unselected: |\n",
      "|||\n",
      "|| || || o Induction cycle 2 :unselected: |\n",
      "|| || . Days 1-28: 28 mcg/day |\n",
      "|| || . Days 29-42: 14-day treatment-free interval |\n",
      "|| || o Consolidation cycles 3-5 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval\n",
      "|| || :unselected: :unselected: | o Continued therapy cycles 6-9 Days 1-28: 28 mcg/day . · Days 29-84: 56-day treatment-free interval |\n",
      "|| || Patients < 45 kg based on body surface area (BSA) • o Induction cycle 1 :unselected: . Days 1-7: 5 mcg/m2/day |\n",
      "|||\n",
      "|| || || Days 8-28: 15 mcg/m2/day . |\n",
      "|| || . Days 29-42: 14-day treatment-free interval |\n",
      "|| || o Induction cycle 2\n",
      "|\n",
      "|| || . :unselected: || || \" Days 1-28: 15 mcg/m2/day | Days 29-42: 14-day treatment-free interval |\n",
      "|| || o :unselected: Consolidation cycles 3-5 |\n",
      "|| || . Days 1-28: 15 mcg/m2/day . Days 29-42: 14-day treatment-free interval |\n",
      "|||\n",
      "|| || || :unselected: o Continued therapy cycles 6-9 . Days 1-28: 15 mcg/m2/day |\n",
      "|| || Days 29-84: 56-day treatment-free interval || |\n",
      "\n",
      "\n",
      "# VI. Product Availability\n",
      "\n",
      "Single-dose vial for reconstitution: 35 mcg\n",
      "\n",
      "VII. References\n",
      "\n",
      "<!-- PageNumber=\"Page 3 of 4\" -->\n",
      "<figure>\n",
      "\n",
      "![](figures/3)\n",
      "\n",
      "<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\n",
      "\n",
      "</figure>\n",
      "\n",
      "\n",
      "CLINICAL POLICY Blinatumomab\n",
      "\n",
      "1\\. Blincyto Prescribing Information. Thousand Oaks, CA: Amgen, Inc .; March 2018. Available at: http://pi.amgen.com/\\~/media/amgen/repositorysites/pi-amgen- com/blincyto/blincyto\\_pi\\_hcp\\_english.ashx. Accessed April 2018.\n",
      "\n",
      "2\\. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed April 2018.\n",
      "\n",
      "3\\. National Comprehensive Cancer Network Guidelines. Acute lymphoblastic leukemia; Version 1.2018. Available at nccn.org. Accessed April 2018.\n",
      "\n",
      "4\\. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc .; 2018. Available at http://www.clinicalpharmacology-ip.com/.\n",
      "\n",
      "5\\. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; doi: https://doi.org/10.1182/blood-2017-08- 798322.\n",
      "\n",
      "6\\. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017 Jun 1; 35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29.\n",
      "\n",
      "7\\. Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 2015; 126: 746-756.\n",
      "\n",
      "8\\. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Longterm efficacy and safety of bosutinib in patients with advanced leukemia following resistance/ intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90:755-768.\n",
      "\n",
      "| Reviews, Revisions, and Approvals | Date | P&T Approval Date |\n",
      "| - | - | - |\n",
      "| Policy created. | 05.08.18 | 08.18 |\n",
      "\n",
      "\n",
      "## Important Reminder\n",
      "\n",
      "This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.\n",
      "\n",
      "This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.\n",
      "\n",
      "This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.\n",
      "\n",
      "2018 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.\n",
      "\n",
      "<!-- PageNumber=\"Page 4 of 4\" -->\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "**Instructions:**\n",
      "\n",
      "- Conduct a thorough analysis by comparing each piece of provided information against the corresponding policy criteria.\n",
      "- Extract all necessary information from both the policy text and the provided data.\n",
      "- Use a detailed comparison to evaluate how the request aligns with the policy requirements.\n",
      "- Base your decision solely on the provided information and policy text.\n",
      "- Do not include personal opinions or make assumptions beyond the given data.\n",
      "\n",
      "---\n",
      "\n",
      "**Output Format:**\n",
      "\n",
      "**Final Decision**\n",
      "\n",
      "[Approved / Denied / Needs More Information]\n",
      "\n",
      "**Rationale**\n",
      "\n",
      "**Summary of Findings**\n",
      "\n",
      "- Briefly summarize how the request aligns with the policy criteria.\n",
      "\n",
      "**Detailed Analysis**\n",
      "\n",
      "**Policy Criteria Assessment**\n",
      "\n",
      "- Criterion 1: [State the criterion]\n",
      "  - Assessment: Fully Met / Partially Met / Not Met\n",
      "  - Evidence: Cite specific information from the patient or physician details.\n",
      "  - Policy Reference: Cite relevant sections from the policy text.\n",
      "- Criterion 2: [State the criterion]\n",
      "  - Assessment: Fully Met / Partially Met / Not Met\n",
      "  - Evidence: ...\n",
      "  - Policy Reference: ...\n",
      "  - (Continue for all relevant criteria)\n",
      "\n",
      "**Missing Information (if applicable)**\n",
      "\n",
      "- Information Needed: Specify what is missing.\n",
      "- Reason: Explain why this information is necessary according to the policy.\n",
      "\n",
      "---\n",
      "\n",
      "**Note:**\n",
      "\n",
      "- Ensure that all conclusions are based solely on the provided information and policy text.\n",
      "- Do not make assumptions beyond what is given.\n",
      "- Provide clear and concise justifications for each assessment. (run.py:generate_final_determination:661)\n",
      "2024-11-18 18:24:34,453 - PAProcessing - MainProcess - INFO     Using o1 model for final determination for db96f016... (run.py:generate_final_determination:685)\n",
      "2024-11-18 18:24:34,458 - micro - MainProcess - INFO     Function generate_chat_response_o1 started at 2024-11-18 18:24:34 (aoai_helper.py:generate_chat_response_o1:264)\n",
      "2024-11-18 18:24:34,459 - micro - MainProcess - INFO     Sending request to Azure OpenAI at 2024-11-18 18:24:34 (aoai_helper.py:generate_chat_response_o1:272)\n",
      "2024-11-18 18:25:13,166 - micro - MainProcess - INFO     Model_used: o1-preview-2024-09-12 (aoai_helper.py:generate_chat_response_o1:296)\n",
      "2024-11-18 18:25:13,169 - micro - MainProcess - INFO     Function generate_chat_response_o1 finished at 2024-11-18 18:25:13 (Duration: 38.71 seconds) (aoai_helper.py:generate_chat_response_o1:305)\n",
      "2024-11-18 18:25:13,169 - PAProcessing - MainProcess - INFO     \n",
      "Final Determination:\n",
      "**Final Decision**\n",
      "\n",
      "Approved\n",
      "\n",
      "**Rationale**\n",
      "\n",
      "The prior authorization request for Blinatumomab (Blincyto) is approved because the patient meets all the criteria outlined in the policy text for initial approval. The patient has a diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL) in remission but positive for minimal residual disease (MRD+), the medication is prescribed by a qualified specialist, and the requested dosage does not exceed the maximum allowed.\n",
      "\n",
      "**Summary of Findings**\n",
      "\n",
      "- The patient, Lucas Little, is diagnosed with B-cell precursor acute lymphoblastic leukemia (B-ALL) and is MRD positive.\n",
      "- The prescribing physician is a specialist in Pediatric Hematology and Oncology.\n",
      "- The requested treatment is for B-ALL in remission but MRD positive.\n",
      "- The requested dosage of Blinatumomab is 28 mcg/day, which is within the policy limits.\n",
      "- All policy criteria for approval are fully met based on the provided information.\n",
      "\n",
      "**Detailed Analysis**\n",
      "\n",
      "**Policy Criteria Assessment**\n",
      "\n",
      "- **Criterion 1: Diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL)**\n",
      "  - **Assessment:** Fully Met\n",
      "  - **Evidence:** The patient is diagnosed with B-cell precursor acute lymphoblastic leukemia (B-ALL).\n",
      "    - *Clinical Information:* \"Diagnosis: B-cell precursor acute lymphoblastic leukemia (B-ALL)\"\n",
      "  - **Policy Reference:** I.A.1\n",
      "\n",
      "- **Criterion 2: Prescribed by or in consultation with an oncologist or hematologist**\n",
      "  - **Assessment:** Fully Met\n",
      "  - **Evidence:** The medication is prescribed by Dr. Oncoso, who specializes in Pediatric Hematology and Oncology.\n",
      "    - *Physician Information:* \"Specialty: Pediatric Hematology and Oncology\"\n",
      "  - **Policy Reference:** I.A.2\n",
      "\n",
      "- **Criterion 3: Requested as treatment for (a or b):**\n",
      "  - **a. B-ALL in remission but positive for minimal residual disease (MRD+)**\n",
      "    - **Assessment:** Fully Met\n",
      "    - **Evidence:** The patient is in remission with MRD positive status.\n",
      "      - *Clinical Information:*\n",
      "        - \"Blast Cell Percentage: Less than 5% blast cells, consistent with clinical remission\"\n",
      "        - \"Minimal Residual Disease (MRD) Status: Positive for minimal residual disease (MRD+)\"\n",
      "    - **Policy Reference:** I.A.3a\n",
      "\n",
      "- **Criterion 4: Dose does not exceed 28 mcg/day**\n",
      "  - **Assessment:** Fully Met\n",
      "  - **Evidence:** The requested dosage is 28 mcg/day.\n",
      "    - *Treatment Plan:* \"Dosage: 28 mcg/day\"\n",
      "  - **Policy Reference:** I.A.4\n",
      "\n",
      "**Missing Information**\n",
      "\n",
      "- None\n",
      "\n",
      "---\n",
      "\n",
      "**Note:**\n",
      "\n",
      "All conclusions are based solely on the provided information and policy text. (run.py:generate_final_determination:734)\n",
      "2024-11-18 18:25:13,171 - PAProcessing - MainProcess - DEBUG    Data logged for case 'db96f016' at step 'llm_determination'. (run.py:log_output:333)\n",
      "2024-11-18 18:25:13,180 - PAProcessing - MainProcess - INFO     Cleaned up temporary directory: C:\\Users\\pablosal\\AppData\\Local\\Temp\\tmpm1sa9v0t (run.py:cleanup_temp_dir:370)\n",
      "2024-11-18 18:25:14,392 - PAProcessing - MainProcess - INFO     Results stored in Cosmos DB for caseId db96f016 (run.py:store_output:353)\n",
      "2024-11-18 18:25:14,395 - PAProcessing - MainProcess - INFO     PAprocessing completed for db96f016. Execution time: 82.01 seconds. (run.py:run:849)\n"
     ]
    }
   ],
   "source": [
    "await pa_pipeline.run(uploaded_files=files, use_o1=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'51b3bcd3': {'raw_uploaded_files': ['https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51b3bcd3/raw_uploaded_files/003_a (note) .pdf',\n",
       "   'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51b3bcd3/raw_uploaded_files/003_a (labs).pdf',\n",
       "   'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51b3bcd3/raw_uploaded_files/003_a (form).pdf'],\n",
       "  'processed_images': ['https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51b3bcd3/processed_images/003_a (form)-page-1.png',\n",
       "   'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51b3bcd3/processed_images/003_a (form)-page-2.png'],\n",
       "  'patient_name': 'Lucas Little',\n",
       "  'patient_date_of_birth': '07/30/2017',\n",
       "  'patient_id': '345987',\n",
       "  'patient_address': '28 Dearborn St, Chicago, IL, 60602',\n",
       "  'patient_phone_number': '555-360-8746',\n",
       "  'physician_name': 'Dr. John A. Smith, MD',\n",
       "  'specialty': 'Cardiology',\n",
       "  'physician_contact': {'office_phone': '(123) 456-7890',\n",
       "   'fax': '(123) 456-7891',\n",
       "   'office_address': '123 Medical Plaza, Suite 456, Springfield, IL 62704'},\n",
       "  'diagnosis': 'B-cell precursor acute lymphoblastic leukemia (B-ALL); Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal Residual Disease (MRD+)',\n",
       "  'icd_10_code': 'C91.00',\n",
       "  'prior_treatments_and_results': 'Vincristine: Administered weekly; Dexamethasone: Administered daily for 28 days; L-asparaginase: Administered on alternate days; Daunorubicin: Given as a single dose during the first week; Methotrexate: High-dose, given weekly; Mercaptopurine: Daily oral administration; Vincristine: Administered biweekly; Cyclophosphamide: Given during the third week; Doxorubicin: Administered during the final week of consolidation',\n",
       "  'specific_drugs_taken_and_failures': 'Vincristine: Administered weekly; Dexamethasone: Administered daily for 28 days; L-asparaginase: Administered on alternate days; Daunorubicin: Given as a single dose during the first week; Methotrexate: High-dose, given weekly; Mercaptopurine: Daily oral administration; Vincristine: Administered biweekly; Cyclophosphamide: Given during the third week; Doxorubicin: Administered during the final week of consolidation',\n",
       "  'alternative_drugs_required': 'Not provided',\n",
       "  'relevant_lab_results_or_imaging': 'White Blood Cell Count (WBC): 4,500 - 10,000 cells/µL; Neutrophils: 40%; Lymphocytes: 20%; Monocytes: 2%; Eosinophils: 1%; Basophils: 0%; Hemoglobin (Hgb): 11.5 g/dL; Hematocrit (Hct): 35%; Platelet Count: 150,000 cells/µL; Bone Marrow Cellularity: Hypercellular (approximately 90% cellularity); Blast Cell Percentage: Less than 5% blast cells, consistent with clinical remission; Minimal Residual Disease (MRD) Status: Positive for minimal residual disease (MRD+); Leukemic Cell Percentage: 0.1% leukemic cells detected',\n",
       "  'symptom_severity_and_impact': 'Positive for fatigue; Patient has mild fatigue and decreased energy, but is overall well appearing with no recent fevers',\n",
       "  'prognosis_and_risk_if_not_approved': 'The presence of minimal residual disease suggests residual leukemic activity. Continuous monitoring and further therapeutic intervention may be warranted',\n",
       "  'clinical_rationale_for_urgency': 'Not provided',\n",
       "  'treatment_request': {'name_of_medication_or_procedure': 'Blinatumomab',\n",
       "   'code_of_medication_or_procedure': 'Not provided',\n",
       "   'dosage': '28 mcg/day',\n",
       "   'duration': 'Induction cycle 1: Days 1-28: 28 mcg/day; Based on clinical response, up to 6 months',\n",
       "   'rationale': 'Initiate Blinatumomab therapy for management of MRD+ B-ALL',\n",
       "   'presumed_eligibility': 'Yes'},\n",
       "  'optimized_query': 'Prior authorization for Blinatumomab for B-cell precursor acute lymphoblastic leukemia (B-ALL), Philadelphia chromosome-negative B-ALL, Minimal Residual Disease (MRD+). Related terms: B-ALL, B-cell ALL, acute lymphoblastic leukemia, acute lymphocytic leukemia, Philadelphia chromosome-negative ALL, MRD positive, minimal residual disease positive, Blincyto, CD19-targeted therapy, bispecific T-cell engager, BiTE, immunotherapy for leukemia, 28 mcg/day dosage, induction cycle, leukemia treatment, hematologic malignancy, blood cancer, chemotherapy, targeted therapy, monoclonal antibody, ICD-10: C91.00, C91.01, C91.02, CPT: 96413, 96415, 96417.',\n",
       "  'policy_location': 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/003.pdf',\n",
       "  'policy_text': '<figure>\\n\\n![](figures/0)\\n\\n<!-- FigureContent=\"envolve. Pharmacy Solutions\" -->\\n\\n</figure>\\n\\n\\nClinical Policy: Blinatumomab (Blincyto) Reference Number: ERX.SPA.241 Effective Date: 09.01.18 Last Review Date: 08.18\\n\\nRevision Log\\n\\nSee Important Reminder at the end of this policy for important regulatory and legal information.\\n\\nDescription Blinatumomab (Blincyto®) is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells).\\n\\n\\n# FDA Approved Indication(s) Blincyto is indicated for:\\n\\n• MRD-positive B-cell precursor ALL\\n\\no Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\\n\\n· Relapsed or refractory B-cell precursor ALL\\n\\no Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.\\n :unselected:\\nPolicy/Criteria\\n\\nProvider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.\\n\\nIt is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Blincyto is medically necessary when the following criteria are met:\\n\\nI. Initial Approval Criteria\\n\\nA. Acute Lymphoblastic Leukemia (must meet all):\\n\\n1\\\\. Diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL);\\n\\n2\\\\. Prescribed by or in consultation with an oncologist or hematologist;\\n\\n3\\\\. Requested as treatment for (a or b):\\n\\na. B-ALL in remission but positive for minimal residual disease (MRD+);\\n\\nb. Relapsed or refractory B-ALL (i and ii):\\n\\ni. Philadelphia chromosome-negative (Ph-) disease;\\n\\nii. Philadelphia chromosome-positive (Ph+) disease and intolerant or refractory to at least one second-generation or later tyrosine kinase inhibitor (TKI; i.e., Sprycel®, Tasigna®, Bosulif®, Iclusig®);\\n\\n\\\\*Prior authorization is (or may be) required for these agents\\n\\n4\\\\. Dose does not exceed 28 mcg/day. Approval duration: 6 months\\n\\nB. Other diagnoses/indications\\n\\n1\\\\. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III\\n\\n(Diagnoses/Indications for which coverage is NOT authorized).\\n\\n\\n# II. Continued Therapy\\n\\nA. Acute Lymphoblastic Leukemia (must meet all):\\n\\n1\\\\. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Blincyto for a covered indication and has received this medication for at least 30 days;\\n\\n2\\\\. Member is responding positively to therapy;\\n\\n<!-- PageNumber=\"Page 1 of 4\" -->\\n\\n<!-- PageHeader=\"CLINICAL POLICY Blinatumomab\" -->\\n\\n<figure>\\n\\n![](figures/1)\\n\\n<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\\n\\n</figure>\\n\\n\\n3\\\\. If request is for a dose increase, new dose does not exceed 28 mcg/day. Approval duration: 12 months\\n\\nB. Other diagnoses/indications (must meet 1 or 2):\\n\\n1\\\\. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.\\n\\nApproval duration: Duration of request or 6 months (whichever is less); or\\n\\n2\\\\. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).\\n\\nIII. Diagnoses/Indications for which coverage is NOT authorized:\\n\\nA. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy - ERX.PA.01 or evidence of coverage documents.\\n\\n\\n# IV. Appendices/General Information\\n\\nAppendix A: Abbreviation/Acronym Key B-ALL: B-cell precursor acute lymphoblastic leukemia CR: complete remission\\n\\nFDA: Food and Drug Administration MRD+: positive minimal residual disease TKI: tyrosine kinase inhibitor\\n\\nAppendix B: Therapeutic Alternatives This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.\\n\\n| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |\\n| - | - | - |\\n| Sprycel® (dasatinib) | 140 mg PO QD (adults\\\\*) | 180 mg/day |\\n| Iclusig® (ponatinib) | 45 mg PO QD (adults\\\\*) | 45 mg/day |\\n| Tasigna® (nilotinib) | 400 mg PO BID (off-label use; adults\\\\* - as referenced in Kim, et al., 2015; see also Appendix D) | 800 mg/day |\\n| Bosulif® (bosutinib) | 500 to 600 mg PO QD (off-label use; adults\\\\* - as referenced in Gambacroti-Passerini, et al., 2015; see also Appendix D). | 600 mg/day |\\n\\nTherapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.\\n\\n\\\\*Sprycel and Iclusig are FDA approved for Ph+ ALL in adults; however, all four listed TKIs are NCCN recommended (category 2A) for Ph+ ALL in both adults and adolescents/young adults.\\n\\nAppendix C: Contraindications Not applicable\\n\\nAppendix D: General Information\\n\\n. MRD-positive B-cell precursor ALL\\n\\nIn 2018, Blincyto received FDA approval for MRD+ B-ALL in remission based on a single- o arm, open label study (BLAST) showing complete MRD response in a majority of adults undergoing Blincyto therapy; the new FDA indication includes both children and adults based on this pivotal trial.\\n\\no In 2017, blinatumomab\\'s labeled use was expanded from treatment of Ph- relapsed/refractory • Relapsed or refractory B-cell precursor ALL\\n\\nB-ALL to treatment of Ph+ disease based on a single-arm, open label study (ALCANTARAA) showing complete remission (CR), or CR with partial hematologic recovery, after disease progression on at least one second- or thid-generation TKI. FDA approved second- and third- generation TKIs for Ph+ ALL in adults include Sprycel and Iclusig. NCCN recommended (category 2A) TKIs for Ph+ ALL in adults and adolescents/young adults include Sprycel, Iclusig, Tasigna and Bosulif.\\n\\n<!-- PageNumber=\"Page 2 of 4\" -->\\n\\nCLINICAL POLICY Blinatumomab\\n\\n<figure>\\n\\n![](figures/2)\\n\\n<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\\n\\n</figure>\\n\\n\\n\\n# V. Dosage and Administration\\n\\n| Indication || Dosing Regimen  | Maximum Dose |\\n| - | - | - | - |\\n| B-ALL (MRD+ in | Treatment course: 1 cycle of Blincyto IV for induction followed by up to 3 additional cycles for consolidation. || 28 mcg/day |\\n| remission) | Patients ≥ 45 kg receive a fixed dose • |\\n|| || o Induction cycle 1 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval\\n|| || :unselected: :unselected: | o Consolidation cycles 2-4 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval |\\n|| || Patients < 45 kg based on body surface area (BSA) • |\\n|| || o :unselected: Induction cycle 1 . Days 1-7: 5 mcg/m2/day |\\n|||\\n|| || || · Days 8-28: 15 mcg/m2/day . Days 29-42: 14-day treatment-free interval |\\n|||\\n|| || || :unselected: o Consolidation cycles 2-4 Days 1-28: 15 mcg/m2/day |\\n|| || Days 29-42: 14-day treatment-free interval || |\\n| B-ALL (relapsed or | Treatment course: 2 cycles of Blincyto IV for induction followed by 3 cycles for consolidation and up to 4 cycles of continued therapy. || 28 mcg/day |\\n|||| |\\n| refractory) | Patients ≥ 45 kg receive a fixed dose • |\\n|| || o Induction cycle 1 . Days 1-7: 9 mcg/day . Days 8-28: 28 mcg/day Days 29-42: 14-day treatment-free interval . :unselected: |\\n|||\\n|| || || o Induction cycle 2 :unselected: |\\n|| || . Days 1-28: 28 mcg/day |\\n|| || . Days 29-42: 14-day treatment-free interval |\\n|| || o Consolidation cycles 3-5 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval\\n|| || :unselected: :unselected: | o Continued therapy cycles 6-9 Days 1-28: 28 mcg/day . · Days 29-84: 56-day treatment-free interval |\\n|| || Patients < 45 kg based on body surface area (BSA) • o Induction cycle 1 :unselected: . Days 1-7: 5 mcg/m2/day |\\n|||\\n|| || || Days 8-28: 15 mcg/m2/day . |\\n|| || . Days 29-42: 14-day treatment-free interval |\\n|| || o Induction cycle 2\\n|\\n|| || . :unselected: || || \" Days 1-28: 15 mcg/m2/day | Days 29-42: 14-day treatment-free interval |\\n|| || o :unselected: Consolidation cycles 3-5 |\\n|| || . Days 1-28: 15 mcg/m2/day . Days 29-42: 14-day treatment-free interval |\\n|||\\n|| || || :unselected: o Continued therapy cycles 6-9 . Days 1-28: 15 mcg/m2/day |\\n|| || Days 29-84: 56-day treatment-free interval || |\\n\\n\\n# VI. Product Availability\\n\\nSingle-dose vial for reconstitution: 35 mcg\\n\\nVII. References\\n\\n<!-- PageNumber=\"Page 3 of 4\" -->\\n<figure>\\n\\n![](figures/3)\\n\\n<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\\n\\n</figure>\\n\\n\\nCLINICAL POLICY Blinatumomab\\n\\n1\\\\. Blincyto Prescribing Information. Thousand Oaks, CA: Amgen, Inc .; March 2018. Available at: http://pi.amgen.com/\\\\~/media/amgen/repositorysites/pi-amgen- com/blincyto/blincyto\\\\_pi\\\\_hcp\\\\_english.ashx. Accessed April 2018.\\n\\n2\\\\. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed April 2018.\\n\\n3\\\\. National Comprehensive Cancer Network Guidelines. Acute lymphoblastic leukemia; Version 1.2018. Available at nccn.org. Accessed April 2018.\\n\\n4\\\\. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc .; 2018. Available at http://www.clinicalpharmacology-ip.com/.\\n\\n5\\\\. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; doi: https://doi.org/10.1182/blood-2017-08- 798322.\\n\\n6\\\\. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017 Jun 1; 35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29.\\n\\n7\\\\. Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 2015; 126: 746-756.\\n\\n8\\\\. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Longterm efficacy and safety of bosutinib in patients with advanced leukemia following resistance/ intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90:755-768.\\n\\n| Reviews, Revisions, and Approvals | Date | P&T Approval Date |\\n| - | - | - |\\n| Policy created. | 05.08.18 | 08.18 |\\n\\n\\n## Important Reminder\\n\\nThis clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.\\n\\nThis Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.\\n\\nThis policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.\\n\\n2018 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.\\n\\n<!-- PageNumber=\"Page 4 of 4\" -->\\n',\n",
       "  'final_determination': '**Final Decision**\\n\\nApproved\\n\\n**Rationale**\\n\\nAll policy criteria for the approval of Blinatumomab (Blincyto) are fully met based on the provided patient information, clinical data, and policy text. The patient has a diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL) in remission but positive for minimal residual disease (MRD+), the medication is prescribed by a qualified specialist, and the requested dosage does not exceed policy limits.\\n\\n**Summary of Findings**\\n\\n- The patient, Lucas Little, is diagnosed with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) and is currently in clinical remission but MRD positive.\\n- The medication is prescribed by Dr. Oncoso, a specialist in Pediatric Hematology and Oncology.\\n- The treatment plan requests Blinatumomab at a dosage of 28 mcg/day, which aligns with the policy maximum.\\n- All criteria outlined in the policy text are fully met.\\n\\n**Detailed Analysis**\\n\\n**Policy Criteria Assessment**\\n\\n- **Criterion 1: Diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL)**\\n  - **Assessment:** Fully Met\\n  - **Evidence:** The patient\\'s diagnosis includes \"B-cell precursor acute lymphoblastic leukemia (B-ALL); Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal Residual Disease (MRD+).\"\\n  - **Policy Reference:** \"*I. Initial Approval Criteria A. Acute Lymphoblastic Leukemia (must meet all): 1. Diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL);*\"\\n\\n- **Criterion 2: Prescribed by or in consultation with an oncologist or hematologist**\\n  - **Assessment:** Fully Met\\n  - **Evidence:** The prescribing physician is Dr. Oncoso, whose specialty is Pediatric Hematology and Oncology.\\n  - **Policy Reference:** \"*I. Initial Approval Criteria A. Acute Lymphoblastic Leukemia (must meet all): 2. Prescribed by or in consultation with an oncologist or hematologist;*\"\\n\\n- **Criterion 3: Requested as treatment for B-ALL in remission but positive for minimal residual disease (MRD+)**\\n  - **Assessment:** Fully Met\\n  - **Evidence:** Clinical information indicates the patient is in clinical remission (\"Blast Cell Percentage: Less than 5% blast cells, consistent with clinical remission\") but MRD positive (\"Minimal Residual Disease (MRD) Status: Positive for minimal residual disease (MRD+); Leukemic Cell Percentage: 0.1% leukemic cells detected\").\\n  - **Policy Reference:** \"*I. Initial Approval Criteria A. Acute Lymphoblastic Leukemia (must meet all): 3. Requested as treatment for (a or b): a. B-ALL in remission but positive for minimal residual disease (MRD+);*\"\\n\\n- **Criterion 4: Dose does not exceed 28 mcg/day**\\n  - **Assessment:** Fully Met\\n  - **Evidence:** The treatment plan specifies a dosage of 28 mcg/day.\\n  - **Policy Reference:** \"*I. Initial Approval Criteria A. Acute Lymphoblastic Leukemia (must meet all): 4. Dose does not exceed 28 mcg/day.*\"\\n\\n**Missing Information**\\n\\n- **None**. All required information has been provided and all policy criteria are fully met.'}}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pa_pipeline.results"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Query from Cosmos DB"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\src\\cosmosdb\\cosmosmongodb_helper.py:31: UserWarning: You appear to be connected to a CosmosDB cluster. For more information regarding feature compatibility and support please visit https://www.mongodb.com/supportability/cosmosdb\n",
      "  self.client = pymongo.MongoClient(connection_string)\n"
     ]
    }
   ],
   "source": [
    "from src.cosmosdb.cosmosmongodb_helper import CosmosDBMongoCoreManager\n",
    "\n",
    "session_State = CosmosDBMongoCoreManager(\n",
    "    connection_string=os.getenv(\"AZURE_COSMOS_CONNECTION_STRING\"),\n",
    "    database_name=os.getenv(\"AZURE_COSMOS_DB_DATABASE_NAME\"),\n",
    "    collection_name=os.getenv(\"AZURE_COSMOS_DB_COLLECTION_NAME\"),\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "query = {\"caseId\": \"280e837a\"}\n",
    "document = session_State.read_document(query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'_id': ObjectId('673b89a0d3124698e29a57cb'),\n",
       " 'caseId': '280e837a',\n",
       " 'raw_uploaded_files': ['https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51fedadb/raw_uploaded_files/003_a (form).pdf',\n",
       "  'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51fedadb/raw_uploaded_files/003_a (labs).pdf',\n",
       "  'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51fedadb/raw_uploaded_files/003_a (note) .pdf'],\n",
       " 'processed_images': ['https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51fedadb/processed_images/003_a (note) -page-1.png',\n",
       "  'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51fedadb/processed_images/003_a (note) -page-2.png',\n",
       "  'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/pa_proccesing_runs/51fedadb/processed_images/003_a (note) -page-3.png'],\n",
       " 'patient_name': 'Lucas Little',\n",
       " 'patient_date_of_birth': '07/30/2017',\n",
       " 'patient_id': '345987',\n",
       " 'patient_address': '28 Dearborn St, Chicago, IL, 60602',\n",
       " 'patient_phone_number': '555-360-8746',\n",
       " 'physician_name': 'Dr. Oncoso',\n",
       " 'specialty': 'Pediatric Hematology and Oncology',\n",
       " 'physician_contact': {'office_phone': '555-324-7878',\n",
       "  'fax': '555-324-7877',\n",
       "  'office_address': '27 W State St, Chicago, IL 60601'},\n",
       " 'diagnosis': 'Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL); Minimal residual disease (MRD+)',\n",
       " 'icd_10_code': 'C91.00',\n",
       " 'prior_treatments_and_results': 'Induction Phase: Vincristine (weekly), Dexamethasone (daily for 28 days), L-asparaginase (alternate days), Daunorubicin (single dose during first week); Consolidation Phase: Methotrexate (high-dose, weekly); Maintenance Phase: Methotrexate (weekly), Mercaptopurine (daily), Vincristine (every 4 weeks), Intrathecal Methotrexate (every 2-3 months)',\n",
       " 'specific_drugs_taken_and_failures': 'Vincristine: Administered weekly; Dexamethasone: Administered daily for 28 days; L-asparaginase: Administered on alternate days; Daunorubicin: Given as a single dose during the first week; Methotrexate: High-dose, given weekly; Mercaptopurine: Daily oral administration; Vincristine: Administered biweekly; Cyclophosphamide: Given during the third week; Doxorubicin: Administered during the final week of consolidation',\n",
       " 'alternative_drugs_required': 'Not provided',\n",
       " 'relevant_lab_results_or_imaging': 'Bone Marrow Biopsy (3/29/24): 85% lymphoblasts, Philadelphia chromosome-negative; Bone Marrow Biopsy (10/4/24): Less than 5% blast cells, MRD+; White Blood Cell Count: 4,500 - 10,000 cells/µL; Neutrophils: 40% - 60%; Lymphocytes: 20% - 40%; Monocytes: 2% - 8%; Eosinophils: 1% - 4%; Basophils: 0% - 1%; Hemoglobin: 11.5 - 15.5 g/dL; Hematocrit: 35% - 45%; Platelet Count: 150,000 - 450,000 cells/µL',\n",
       " 'symptom_severity_and_impact': 'Mild fatigue and decreased energy; No recent fevers; Positive for fatigue',\n",
       " 'prognosis_and_risk_if_not_approved': 'Presence of minimal residual disease suggests residual leukemic activity; Continuous monitoring and further therapeutic intervention may be warranted',\n",
       " 'clinical_rationale_for_urgency': 'Not provided',\n",
       " 'treatment_request': {'name_of_medication_or_procedure': 'Blinatumomab',\n",
       "  'code_of_medication_or_procedure': 'Not provided',\n",
       "  'dosage': '28 mcg/day',\n",
       "  'duration': 'Induction cycle 1: Days 1-28: 28 mcg/day; Based on clinical response, up to 6 months',\n",
       "  'rationale': 'Management of MRD+ B-ALL; Patient has achieved clinical remission with less than 5% blast cells but is positive for minimal residual disease (MRD+)',\n",
       "  'presumed_eligibility': 'Patient has a diagnosis of B-cell acute lymphoblastic leukemia (ALL); Patient is in the consolidation phase of multiphase chemotherapy; Patient has minimal residual disease (MRD+); Patient has Philadelphia chromosome-negative ALL'},\n",
       " 'optimized_query': 'Prior authorization for Blinatumomab for Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD+). Related terms: Blincyto, B-ALL, B-cell ALL, acute lymphoblastic leukemia, acute lymphocytic leukemia, minimal residual disease, MRD positive, MRD+, Ph-negative, Philadelphia chromosome-negative, B-cell precursor leukemia, induction therapy, 28 mcg/day, clinical remission, less than 5% blast cells, up to 6 months treatment, immunotherapy, bispecific T-cell engager, BiTE, CD19, CD3, targeted therapy.',\n",
       " 'policy_location': 'https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/003.pdf',\n",
       " 'policy_text': '<figure>\\n\\n![](figures/0)\\n\\n<!-- FigureContent=\"envolve. Pharmacy Solutions\" -->\\n\\n</figure>\\n\\n\\nClinical Policy: Blinatumomab (Blincyto) Reference Number: ERX.SPA.241 Effective Date: 09.01.18 Last Review Date: 08.18\\n\\nRevision Log\\n\\nSee Important Reminder at the end of this policy for important regulatory and legal information.\\n\\nDescription Blinatumomab (Blincyto®) is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells).\\n\\n\\n# FDA Approved Indication(s) Blincyto is indicated for:\\n\\n• MRD-positive B-cell precursor ALL\\n\\no Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.\\n\\n· Relapsed or refractory B-cell precursor ALL\\n\\no Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.\\n :unselected:\\nPolicy/Criteria\\n\\nProvider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.\\n\\nIt is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Blincyto is medically necessary when the following criteria are met:\\n\\nI. Initial Approval Criteria\\n\\nA. Acute Lymphoblastic Leukemia (must meet all):\\n\\n1\\\\. Diagnosis of B-cell precursor acute lymphoblastic leukemia (B-ALL);\\n\\n2\\\\. Prescribed by or in consultation with an oncologist or hematologist;\\n\\n3\\\\. Requested as treatment for (a or b):\\n\\na. B-ALL in remission but positive for minimal residual disease (MRD+);\\n\\nb. Relapsed or refractory B-ALL (i and ii):\\n\\ni. Philadelphia chromosome-negative (Ph-) disease;\\n\\nii. Philadelphia chromosome-positive (Ph+) disease and intolerant or refractory to at least one second-generation or later tyrosine kinase inhibitor (TKI; i.e., Sprycel®, Tasigna®, Bosulif®, Iclusig®);\\n\\n\\\\*Prior authorization is (or may be) required for these agents\\n\\n4\\\\. Dose does not exceed 28 mcg/day. Approval duration: 6 months\\n\\nB. Other diagnoses/indications\\n\\n1\\\\. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III\\n\\n(Diagnoses/Indications for which coverage is NOT authorized).\\n\\n\\n# II. Continued Therapy\\n\\nA. Acute Lymphoblastic Leukemia (must meet all):\\n\\n1\\\\. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Blincyto for a covered indication and has received this medication for at least 30 days;\\n\\n2\\\\. Member is responding positively to therapy;\\n\\n<!-- PageNumber=\"Page 1 of 4\" -->\\n\\n<!-- PageHeader=\"CLINICAL POLICY Blinatumomab\" -->\\n\\n<figure>\\n\\n![](figures/1)\\n\\n<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\\n\\n</figure>\\n\\n\\n3\\\\. If request is for a dose increase, new dose does not exceed 28 mcg/day. Approval duration: 12 months\\n\\nB. Other diagnoses/indications (must meet 1 or 2):\\n\\n1\\\\. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.\\n\\nApproval duration: Duration of request or 6 months (whichever is less); or\\n\\n2\\\\. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).\\n\\nIII. Diagnoses/Indications for which coverage is NOT authorized:\\n\\nA. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy - ERX.PA.01 or evidence of coverage documents.\\n\\n\\n# IV. Appendices/General Information\\n\\nAppendix A: Abbreviation/Acronym Key B-ALL: B-cell precursor acute lymphoblastic leukemia CR: complete remission\\n\\nFDA: Food and Drug Administration MRD+: positive minimal residual disease TKI: tyrosine kinase inhibitor\\n\\nAppendix B: Therapeutic Alternatives This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.\\n\\n| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |\\n| - | - | - |\\n| Sprycel® (dasatinib) | 140 mg PO QD (adults\\\\*) | 180 mg/day |\\n| Iclusig® (ponatinib) | 45 mg PO QD (adults\\\\*) | 45 mg/day |\\n| Tasigna® (nilotinib) | 400 mg PO BID (off-label use; adults\\\\* - as referenced in Kim, et al., 2015; see also Appendix D) | 800 mg/day |\\n| Bosulif® (bosutinib) | 500 to 600 mg PO QD (off-label use; adults\\\\* - as referenced in Gambacroti-Passerini, et al., 2015; see also Appendix D). | 600 mg/day |\\n\\nTherapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.\\n\\n\\\\*Sprycel and Iclusig are FDA approved for Ph+ ALL in adults; however, all four listed TKIs are NCCN recommended (category 2A) for Ph+ ALL in both adults and adolescents/young adults.\\n\\nAppendix C: Contraindications Not applicable\\n\\nAppendix D: General Information\\n\\n. MRD-positive B-cell precursor ALL\\n\\nIn 2018, Blincyto received FDA approval for MRD+ B-ALL in remission based on a single- o arm, open label study (BLAST) showing complete MRD response in a majority of adults undergoing Blincyto therapy; the new FDA indication includes both children and adults based on this pivotal trial.\\n\\no In 2017, blinatumomab\\'s labeled use was expanded from treatment of Ph- relapsed/refractory • Relapsed or refractory B-cell precursor ALL\\n\\nB-ALL to treatment of Ph+ disease based on a single-arm, open label study (ALCANTARAA) showing complete remission (CR), or CR with partial hematologic recovery, after disease progression on at least one second- or thid-generation TKI. FDA approved second- and third- generation TKIs for Ph+ ALL in adults include Sprycel and Iclusig. NCCN recommended (category 2A) TKIs for Ph+ ALL in adults and adolescents/young adults include Sprycel, Iclusig, Tasigna and Bosulif.\\n\\n<!-- PageNumber=\"Page 2 of 4\" -->\\n\\nCLINICAL POLICY Blinatumomab\\n\\n<figure>\\n\\n![](figures/2)\\n\\n<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\\n\\n</figure>\\n\\n\\n\\n# V. Dosage and Administration\\n\\n| Indication || Dosing Regimen  | Maximum Dose |\\n| - | - | - | - |\\n| B-ALL (MRD+ in | Treatment course: 1 cycle of Blincyto IV for induction followed by up to 3 additional cycles for consolidation. || 28 mcg/day |\\n| remission) | Patients ≥ 45 kg receive a fixed dose • |\\n|| || o Induction cycle 1 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval\\n|| || :unselected: :unselected: | o Consolidation cycles 2-4 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval |\\n|| || Patients < 45 kg based on body surface area (BSA) • |\\n|| || o :unselected: Induction cycle 1 . Days 1-7: 5 mcg/m2/day |\\n|||\\n|| || || · Days 8-28: 15 mcg/m2/day . Days 29-42: 14-day treatment-free interval |\\n|||\\n|| || || :unselected: o Consolidation cycles 2-4 Days 1-28: 15 mcg/m2/day |\\n|| || Days 29-42: 14-day treatment-free interval || |\\n| B-ALL (relapsed or | Treatment course: 2 cycles of Blincyto IV for induction followed by 3 cycles for consolidation and up to 4 cycles of continued therapy. || 28 mcg/day |\\n|||| |\\n| refractory) | Patients ≥ 45 kg receive a fixed dose • |\\n|| || o Induction cycle 1 . Days 1-7: 9 mcg/day . Days 8-28: 28 mcg/day Days 29-42: 14-day treatment-free interval . :unselected: |\\n|||\\n|| || || o Induction cycle 2 :unselected: |\\n|| || . Days 1-28: 28 mcg/day |\\n|| || . Days 29-42: 14-day treatment-free interval |\\n|| || o Consolidation cycles 3-5 . Days 1-28: 28 mcg/day . Days 29-42: 14-day treatment-free interval\\n|| || :unselected: :unselected: | o Continued therapy cycles 6-9 Days 1-28: 28 mcg/day . · Days 29-84: 56-day treatment-free interval |\\n|| || Patients < 45 kg based on body surface area (BSA) • o Induction cycle 1 :unselected: . Days 1-7: 5 mcg/m2/day |\\n|||\\n|| || || Days 8-28: 15 mcg/m2/day . |\\n|| || . Days 29-42: 14-day treatment-free interval |\\n|| || o Induction cycle 2\\n|\\n|| || . :unselected: || || \" Days 1-28: 15 mcg/m2/day | Days 29-42: 14-day treatment-free interval |\\n|| || o :unselected: Consolidation cycles 3-5 |\\n|| || . Days 1-28: 15 mcg/m2/day . Days 29-42: 14-day treatment-free interval |\\n|||\\n|| || || :unselected: o Continued therapy cycles 6-9 . Days 1-28: 15 mcg/m2/day |\\n|| || Days 29-84: 56-day treatment-free interval || |\\n\\n\\n# VI. Product Availability\\n\\nSingle-dose vial for reconstitution: 35 mcg\\n\\nVII. References\\n\\n<!-- PageNumber=\"Page 3 of 4\" -->\\n<figure>\\n\\n![](figures/3)\\n\\n<!-- FigureContent=\"envolve Pharmacy Solutions TM\" -->\\n\\n</figure>\\n\\n\\nCLINICAL POLICY Blinatumomab\\n\\n1\\\\. Blincyto Prescribing Information. Thousand Oaks, CA: Amgen, Inc .; March 2018. Available at: http://pi.amgen.com/\\\\~/media/amgen/repositorysites/pi-amgen- com/blincyto/blincyto\\\\_pi\\\\_hcp\\\\_english.ashx. Accessed April 2018.\\n\\n2\\\\. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed April 2018.\\n\\n3\\\\. National Comprehensive Cancer Network Guidelines. Acute lymphoblastic leukemia; Version 1.2018. Available at nccn.org. Accessed April 2018.\\n\\n4\\\\. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc .; 2018. Available at http://www.clinicalpharmacology-ip.com/.\\n\\n5\\\\. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; doi: https://doi.org/10.1182/blood-2017-08- 798322.\\n\\n6\\\\. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017 Jun 1; 35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29.\\n\\n7\\\\. Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 2015; 126: 746-756.\\n\\n8\\\\. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Longterm efficacy and safety of bosutinib in patients with advanced leukemia following resistance/ intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90:755-768.\\n\\n| Reviews, Revisions, and Approvals | Date | P&T Approval Date |\\n| - | - | - |\\n| Policy created. | 05.08.18 | 08.18 |\\n\\n\\n## Important Reminder\\n\\nThis clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.\\n\\nThis Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.\\n\\nThis policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.\\n\\n2018 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.\\n\\n<!-- PageNumber=\"Page 4 of 4\" -->\\n'}"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "document"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "pa-ai-env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
